Flags

Earnings warning

Verastem

NAQ:VSTM · US92337C2035

BiotechnologySmall

360

Medium confidence — indicative

Value—

Profit price—

Cash yield—

Sales & asset price70

Price/Sales93

EV / Gross Profit35

Price/Book82

Quality43

Returns on capital5

Return on Capital9

Return on Equity1

Profit margins73

Cash truth not applicable for financial companies.

Growth50

Sales growth84

Profit growth50

Reinvestment12

Price momentum6

Safety62

Debt load22

Debt serviceability5

Liquidity17

Sentiment50

Analyst ratings78

Expectations trend50

Market mood76

Value Creation13/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Verastem clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQCM

Founded2010

Employees127

Websiteverastem.com

ISINUS92337C2035

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

OncologyBiopharmaBiotechnologyPharmaceutical

Description

Verastem, Inc. is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with challenging RAS/MAPK pathway-driven cancers. The company’s pipeline includes clinical-stage progr…

Analysis

Middle-of-the-road

Verastem, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is sturdy. The company scores 13/20 on our value-creation score: creating some value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Verastem with its peers

ArriVent BioPharma

NMQ:AVBP

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Nuvalent

NSQ:NUVL

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Immuneering

NMQ:IMRX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Elicio Therapeutics

NAQ:ELTX

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Prelude Therapeutics

NSQ:PRLD

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Day One Biopharmaceuticals

NSQ:DAWN

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →